Details

Autor(en) / Beteiligte

• Sequist, Lecia V
• Soria, Jean-Charles
• Goldman, Jonathan W
• Wakelee, Heather A
• Gadgeel, Shirish M
• Varga, Andrea
• Papadimitrakopoulou, Vassiliki
• Solomon, Benjamin J
• Oxnard, Geoffrey R
• Dziadziuszko, Rafal
• Aisner, Dara L
• Doebele, Robert C
• Galasso, Cathy
• Garon, Edward B
• Heist, Rebecca S
• Logan, Jennifer
• Neal, Joel W
• Mendenhall, Melody A
• Nichols, Suzanne
• Piotrowska, Zofia
• Wozniak, Antoinette J
• Raponi, Mitch
• Karlovich, Chris A
• Jaw-Tsai, Sarah
• Isaacson, Jeffrey
• Despain, Darrin
• Matheny, Shannon L
• Rolfe, Lindsey
• Allen, Andrew R
• Camidge, D. Ross

Titel

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Ist Teil von

• The New England journal of medicine, 2015-04, Vol.372 (18), p.1700-1709

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation (T790M) are responsive to rociletinib. Increasingly, treatment decisions for patients with non–small-cell lung cancer (NSCLC) are based on the driver mutation rather than the histologic subtype, when such mutations are present. Mutations in the gene encoding epidermal growth factor receptor ( EGFR ) are among the most common oncogenic mutations in lung adenocarcinoma and are present in approximately 10 to 15% of Western patients and 30 to 35% of Asian patients. 1 At the time of diagnosis, approximately 90% of EGFR -mutation–positive patients have one of two activating mutations, an in-frame deletion in exon 19 or an L858R point mutation in exon 21. 1 The first-generation and . . .